Promoting Your 510(k)-Pending Device: 5 Questions About FDA's Policy
A 510(k) submission rather than a 510(k) clearance is the threshold that a device firm needs to meet to begin advertising or displaying a product under a long-established, one-sentence agency policy. But important questions remain about proper application of this policy by industry, Hyman, Phelps & McNamara attorney Jeffrey Shapiro writes in this guest column.
You may also be interested in...
Together, we will improve patient health and experiences while lowering costs across the continuum of care.” This quote, from Andrew Witty, CEO of US health services management company Optum, after the company sealed its acquisition of DaVita Medical Group in 2019, encapsulates the oft-declared goals of vertical integration: efficiencies, improved quality of care, reduced costs. But is this the reality?
Canada’s Valeo Pharma says it intends to pursue discussions for the inclusion of its Redesca enoxaparin biosimilar on all other provincial formularies, after being backed for listing on the Quebec public health plan.
France's health technology assessment body says that delaying by six weeks the second dose of the two mRNA vaccines approved for use against COVID-19 would allow at least 700,000 more people to receive their jab in the first month.